Physician profile
Ronald Levy
NPI 1851427025
$475,009.52
in general payments reported to CMS, 2019-2025
9 companies · $20K in 2025
The $20K reported for 2025 was more than what 88% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,217 · 2020: $15K · 2021: $368K · 2022: $24K · 2023: $20K · 2024: $25K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $57.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,000.00 |
| Food and Beverage | $57.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $351,721.25 | 2021-2022 | |
| Beigene, Ltd. | $85,000.00 | 2020-2025 | |
| Opko Pharmaceuticals, LLC | $20,000.00 | 2024 | |
| Beone Medicines USA, INC. | $11,666.67 | 2025 | |
| Beone Medicines Ltd. | $3,333.33 | 2025 | |
| Pfizer INC. | $3,200.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $88.27 | 2019-2025 | Rebyota |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.